77067
RadiologyCMS status: AScreening mammography, bilateral. CMS 2026 global wRVU 0.70, total RVU approximately 3.53, Medicare global allowable approximately $118. The annual breast-cancer screening study. Covered with no patient cost share under ACA preventive benefits and Medicare screening rules.
Drop 77067 into a scenario to see how unit volume rolls up to annual wRVUs, gross collections, and bonus.
Open in calculator →When to use it
Use 77067 for routine bilateral screening mammography in an asymptomatic patient meeting eligibility criteria (typically age 40+ for commercial, age 40+ for Medicare). Cannot be used when the patient is symptomatic, has a palpable abnormality, or is being recalled from a prior screening — those are diagnostic mammography (77065 unilateral or 77066 bilateral). Often paired with 77063 (3D tomosynthesis screening add-on) when DBT is performed alongside the 2D screening views.
Documentation checklist
- ✓Order: "screening mammography" with asymptomatic indication, or routine annual screening.
- ✓Patient is asymptomatic, no palpable abnormality, no targeted callback indication.
- ✓Standard four-view mammography (CC and MLO of each breast) performed.
- ✓Interpretation report with BI-RADS category assigned.
- ✓Setting modifier; signed report.
Common pitfalls
- !Billing 77067 for a patient who actually had a palpable lump or focal symptom. That's diagnostic mammography (77065 or 77066) — not screening.
- !Billing 77067 with a 12-month frequency violation. Medicare covers annually (every 11 months actually allowed by CMS); commercial frequency varies but is usually annual.
- !Missing the DBT add-on 77063 when tomosynthesis was performed alongside 2D screening views. 77063 is an add-on code that must be reported with the screening 77067.
- !Confusing 77067 with G0202 (Medicare digital screening). G0202 was the older Medicare-specific HCPCS code; 77067 replaced it for Medicare in recent rule changes — verify your payer's preferred code.
- !Failing to assign a BI-RADS category. The category drives downstream workflow (additional imaging, biopsy referral) and is the structural deliverable of the screen.
Payer notes
Medicare and ACA-compliant commercial plans cover 77067 with no patient cost share when billed as screening (Z12.31 diagnosis). Add 77063 for DBT screening add-on; many payers cover 77063 without separate cost share. Frequency: annual (Medicare every 11 months, commercial typically every 12). If a screening is called back for diagnostic imaging, modifier GG can be used to indicate the screening became diagnostic, preserving the screening cost-share status for Medicare; commercial uses modifier 33 for the equivalent.